Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-qs9v7 Total loading time: 0 Render date: 2024-07-12T23:26:33.570Z Has data issue: false hasContentIssue false

139 - Timolol

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Blocadren (oral), Betimol, Betim, Timoptic, Istalol (ocular solution)

Generic?

• Yes

Class

• β-blocker

Commonly Prescribed for

(FDA approved in bold)

Migraine prophylaxis

Hypertension

Myocardial infarction (MI)

Chronic open-angle glaucoma or ocular hypertension (ocular solution)

• Congestive heart failure (stable)

• Angina pectoris due to coronary atherosclerosis

• Prevention of variceal bleeding

How the Drug Works

• Migraine: proposed mechanisms include inhibition of adrenergic pathway, interaction with serotonin system and receptors, inhibition of nitric oxide production, and normalization of contingent negative variation. Prevention of cortical spreading depression may be one mechanism of action for all migraine preventives

How Long Until It Works

• Migraines: within 2 weeks, but can take up to 3 months on a stable dose to see full effect

If It Works

• In migraine, the goal is a 50% or greater decrease in migraine frequency or severity. Consider tapering or stopping if headaches remit for more than 6 months or if considering pregnancy

If It Doesn't Work

• Increase to highest tolerated dose

• Migraine: address other issues, such as medication overuse, other coexisting medical disorders, such as anxiety, and consider changing to another drug or adding a second drug

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Migraine: for some patients, low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than highdose monotherapy. May use in combination with AEDs, antidepressants, natural products, and non-pharmacological treatments, such as biofeedback, to improve headache control

Tests

• None required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Antagonism of β receptors

Notable AEs

• Bradycardia, hypotension, hyper or hypoglycemia, weight gain

• Bronchospasm, cold/flu symptoms, sinusitis, pneumonias

• Dizziness, vertigo, fatigue/tiredness, depression, sleep disturbances

• Sexual dysfunction, decreased libido, dysuria, urinary retention, joint pain

• Exacerbation of symptoms in peripheral vascular disease and Raynaud's syndrome

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 509 - 512
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Timolol
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.140
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Timolol
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.140
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Timolol
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.140
Available formats
×